This highlights the prognostic relevance of these genetic aberrations, underscoring the importance of molecular markers such as TP53 mutation status in decision-making for CLL patients even in the era of targeted agents [19]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.